Search Results

UroGen Pharma Ltd. today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team.

UroGen Pharma Ltd. announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell its ordinary shares and pre-funded warrants.

UroGen Pharma Ltd. today announced the grants of inducement restricted stock units (“RSUs”) and an option (“Option”) to 15 new employees in connection with their employment with UroGen.

UroGen Pharma Ltd. today shared additional details about the upcoming ENVISION virtual data event on Thursday, June 13, 2024, at 11:00 a.m. Eastern Time.

UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, announced that it will present at the following investor conferences in May.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a fireside chat at the 45th Annual Goldman Sachs Global Healthcare Conference to take place June 10-13, 2024.

UroGen Pharma Ltd. today announced that it will report 2024 first quarter financial results on Monday, May 13, 2024, prior to the open of the stock market.

UroGen Pharma Ltd. announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ordinary share, and, to certain investors in lieu of issuing ordinary shares, pre-funded warrants to purchase 1,142,857 ordinary shares at a purchase price of $17.499 per pre-funded warrant, which equals the public offering price per ordinary share less the $0.001 per share exercise price for each pre-funded warrant.